Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Madrid – page 118

3 294 clinical trials in Madrid, Spain across 24 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Madrid at a glance
3 294
clinical trials
  • Research sites24
Type of trial
Recruitment status
Quick filters

3 294 trials in Madrid

Open in trial search

Sickle cell disease

Not yet recruiting

Study of GBT021601 for Adults and Children with Sickle Cell Disease

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:(S)-2-Hydroxy-6-((4-(2-(2-Hydroxyethyl)Nicotinoyl)Morpholin-3-Yl)Methoxy)Benzaldehyde
  • Sponsor:Global Blood Therapeutics Inc.

Colitis ulcerative

Not yet recruiting

Study on the Safety and Effectiveness of Lutikizumab and Adalimumab for Adults with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Skin cancer+1

Not yet recruiting

Study of DYP688 for Patients with Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dyp688
  • Sponsor:Novartis Pharma AG

Soft tissue sarcoma

Not yet recruiting

Study of Selinexor and Gemcitabine for Patients with Advanced Soft-Tissue Sarcoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Asociacion Europea Y Latinoamericana SELNET Para La Investigacion En Sarcomas

Acute kidney injury

Not yet recruiting

Study on M2RLAB Cell Therapy for Treating Acute Kidney Injury in Patients After Heart Surgery

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:M2Rlab
  • Sponsor:M2rlab S.L.

Non-small cell lung cancer

Not yet recruiting

Study on JDQ443 for First-Line Treatment in Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:1-{6-[(4M)-4-(5-Chloro-6-Methyl-1H -Indazol-4-Yl)-5-Methyl-3-(1-Methyl-1H -Indazol-5-Yl)-1H -Pyrazol-1-Yl]-2-Azaspiro[3.3]Heptan-2-Yl}Prop-2-En-1-One
  • Sponsor:Novartis Pharma AG

Duchenne muscular dystrophy+1

Not yet recruiting

Study on the Safety and Effectiveness of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Delandistrogene Moxeparvovec
  • Sponsor:Sarepta Therapeutics Inc.

Prostate cancer

Not yet recruiting

Study on the Use of 64Cu-PSMA I&T to Detect Lymph Node Spread in Men with Newly Diagnosed Prostate Cancer Before Surgery

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:64CU-PSMA I&T
  • Sponsor:Curium US LLC

Leiomyosarcoma+5

Not yet recruiting

Study on the Effectiveness and Safety of INT230-6 (Vinblastine Sulfate, Cisplatin) for Adults with Metastatic Soft Tissue Sarcomas

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Intensity Therapeutics Inc.

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Novartis Pharma AG

Systemic scleroderma

Not yet recruiting

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Narcolepsy

Not yet recruiting

Study on TAK-861 for Treating Narcolepsy with Cataplexy in Patients

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3',5'-Trifluoro[1,1'-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide
  • Sponsor:Takeda Development Center Americas Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Madrid

What the registry says about research in the country

01 Autoimmune and Inflammatory Conditions

Investigating novel treatments for cutaneous lupus erythematosus and immune thrombocytopenia, with studies evaluating new therapeutic approaches to manage these challenging conditions.

  • Lupus skin manifestations
  • Platelet disorders
  • Immune system regulation

Research focuses on improving treatment outcomes and quality of life for patients with autoimmune disorders.

02 Metabolic and Endocrine Disorders

Clinical trials examining innovative therapies for Type 1 Diabetes in combination with weight management, targeting both glycemic control and obesity-related complications.

  • Diabetes management
  • Weight control
  • Metabolic health

Studies aim to develop comprehensive treatment approaches for complex metabolic conditions.

03 Neurological Conditions

Breakthrough research in multiple sclerosis and acute ischemic stroke, exploring new therapeutic options for both pediatric and adult populations.

  • MS treatment in young patients
  • Stroke intervention
  • Neurological recovery

Focus on developing targeted treatments to improve neurological outcomes and patient care.

04 Infectious Disease Prevention

Comprehensive vaccine studies targeting respiratory syncytial virus, influenza, and herpes zoster, with particular attention to vulnerable populations.

  • Vaccine development
  • Immune response
  • Prevention strategies

Research aims to enhance protection against common and serious infectious diseases.

05 Oncology Research

Innovative studies in mantle cell lymphoma and bladder cancer, exploring combination therapies and targeted treatments to improve patient outcomes.

  • Lymphoma treatment
  • Bladder cancer therapy
  • Immunotherapy approaches

Focus on developing more effective and personalized cancer treatments.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.